Antifolate resistance in Africa and the 164-dollar question

John E. Hyde

    Research output: Contribution to journalArticlepeer-review


    The spread of Plasmodium falciparum carrying a quadruply mutated dhfr gene to Africa has been widely predicted to have profoundly adverse consequences, as such parasites in vitro are highly resistant to antifolate inhibitiors, still a mainstay of antimalarial drug regimes in this region. Studies of parasites from Southeast Asia demonstrate a strong connection between the I164L-bearing quadruple mutant form and failure of sulfadoxine-pyrimethamine (SP) treatment. However, a recent study reported in this issue of Transactions documents the low-level incidence in an area of Kenya of quadruply mutant parasites which, in the majority of cases, appear to have been cleared by a standard SP treatment regime, contrary to expectations. © 2008 Royal Society of Tropical Medicine and Hygiene.
    Original languageEnglish
    Pages (from-to)301-303
    Number of pages2
    JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
    Issue number4
    Publication statusPublished - Apr 2008


    • Dihydrofolate reductase
    • Drug treatment
    • Malaria
    • Plasmodium falciparum
    • Quadruple mutants
    • Sulfadoxine-pyrimethamine


    Dive into the research topics of 'Antifolate resistance in Africa and the 164-dollar question'. Together they form a unique fingerprint.

    Cite this